Milann Unveils Needle-Free Injection Technology for Fertility Treatment Infrastructure

On September 21, 2026, Milann is offering a needle-free injection technology for use in fertility treatment, providing a new choice in assisted reproductive care. The technique is intended to decrease the requirement for conventional needles and to make fertility treatment more comfortable for patients. This advancement reflects an increasing focus on innovation that puts the patient at the centre in the field of reproductive medicine.

 As we know, IVF usually involves a number of injections, so R&D practices towards employing alternative methods of delivery may help to reduce anxiety and enhance the general experience of subcutaneous (SC) and intramuscular (IM) drug delivery. Its broader implementation will depend on the results of clinical trials, compatibility with current medications, safety, regulatory clearance, cost-effectiveness, and the acceptance of both medical specialists and patients.

Impact on the Fertility Sector

The global fertility market size was calculated at USD 39.27 billion in 2025 and is predicted to increase from USD 42.37 billion in 2026 to approximately USD 92.60 billion by 2035, expanding at a CAGR of 8.96% from 2026 to 2035.

According to Precedence Research, patients who feel anxious about repeated injections might find these new methods easier to handle. The initiative of needle-free delivery could give fertility clinics another way to give medications during assisted reproductive treatments and fertility frameworks.

 Clinics may require to update their protocols, train staff, educate patients, and adjust monitoring procedures. If clinical results are positive, this technology could support more patient-focused care in IVF and encourage clinics to reflect new drug-delivery options along with traditional injections.

Impact on the Medical Devices Sector

The global medical devices market was valued at USD 719.61 billion in 2026 and is projected to reach USD 1,209.42 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

According to Precedence Research, as major fertility providers show interest, manufacturers may focus on making medical devices more precise, portable, easy to use, sterile, and comfortable for patients. This development could open new opportunities for medical device companies working on needle-free drug delivery systems.

Fertility care could become a new area for advanced delivery technologies beyond regular syringes. The manufacturers must prove their devices work reliably and achieve regulatory standards that are compatible with medications. Additionally, the rising focus on maintaining and training staff to use them by keeping costs reasonable before these devices are widely used in healthcare infrastructure.

Impact on the Infertility Drugs Sector

The global infertility drugs market size was estimated at USD 4.18 billion in 2025 and is predicted to increase from USD 4.43 billion in 2026 to approximately USD 7.50 billion by 2035, expanding at a CAGR of 6.02% from 2026 to 2035.

According to Precedence Research, gynecologists focus on how stable the medicine is, its thickness, dosage size, packaging, and how accurately it can be delivered, boosting the need for infertility drugs. Needle-free delivery could lead pharmaceutical companies to pay more attention to how their injectable fertility medicines work with new delivery systems.

This technology supports subcutaneous (SC) and intramuscular (IM)drug delivery and encourages more teamwork between drug makers, device companies, and fertility clinics. If more people start using these systems, drug companies might look for ways to make treatments more convenient by ensuring them safe, effective, and reliable solutions.

Expert Opinion

From an expert point of view, Milann’s new technology shows that patient experience is becoming more crucial in fertility treatment. Using fewer traditional needles could help patients who need many injections during IVF. Major factors include delivery accuracy, compatibility with different drugs, treatment outcomes, safety, patient satisfaction, price, and long-term use.

An expert said that this technology promotes subcutaneous (SC) and intramuscular (IM) drug delivery but should be judged on clinical evidence, not just convenience. If these areas show clear benefits, needle-free injections could become a valuable choice in fertility care, with the gynecologist sector working alongside current injection methods instead of replacing them right away.